Design, synthesis, and evaluation of psorospermin/quinobenzoxazine hybrids as structurally novel antitumor agents

Journal of Medicinal Chemistry

Volumn 46, Issue 14, 2003, Pages 2958-2972

  Kim, Mu Yong ^a   Na, Younghwa ^a   Vankayalapati, Hariprasad ^a   Gleason Guzman, Mary ^a   Hurley, Laurence H ^a,b,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 AMINO 1 PYRROLIDINYL) 2 FLUORO 4 OXO 4H QUINO[8,1A,1 B,C][1,4]BENZOXAZINE 5 CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; INTERCALATING AGENT; PLURAMYCIN; PSOROSPERMIN; QUINOBENZOXAZINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CHROMOSOME STRUCTURE; DNA ALKYLATION; DNA METABOLISM; DNA PROTEIN COMPLEX; DRUG DESIGN; DRUG SCREENING; NONHUMAN; PLANT ROOT; STRUCTURE ANALYSIS; SYNTHESIS;

ALKYLATION; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE SEQUENCE; DNA; DNA TOPOISOMERASES, TYPE II; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MAGNESIUM; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OXAZINES; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; XANTHENES; XANTHONES;

EID: 0038460855     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030096i     Document Type: Article

References (43)

1. Cassady, J. M.; Baird, W. M.; Chang, C.-J. Natural products as a source of potential cancer chemotherapeutic and chemopreventive agents. J. Nat. Prod. 1990, 53, 23-41.
2. Kupchan, S. M.; Streelman, D. R.; Sneden, A. T. Psorospermin, a new antileukemic xanthone from Psorospermum febrifugum. J. Nat. Prod. 1980, 43, 296-301.
3. Hansen, M.; Hurley, L. H. Pluramycins. Old drugs having modern friends in structural biology. Acc. Chem. Res. 1996, 29, 249-258.
4. Hansen, M.; Yun, S.; Hurley, L. H. Hedamycin intercalates the DNA helix and, through carbohydrate-mediated recognition in the minor groove, directs N7-alkylation of guanine in the major groove in a sequence-specific manner. Chem. Biol. 1995, 2, 229-240.
5. Hansen, M.; Lee, S.-J.; Cassady, J. M.; Hurley, L. H. Molecular details of the structure of a psorospermin-DNA covalent/intercalation complex and associated DNA sequence selectivity. J. Am. Chem. Soc. 1996, 118, 5553-5561.
6. Kwok, Y.; Zeng, Q.; Hurley, L. H. Topoisomerase II-mediated site-directed alkylation of DNA by psorospermin and its use in mapping other topoisomerase II poison binding sites. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13531-13536.
7. Wang, J. C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 6, 430-440.
8. Watt, P. M.; Hickson, I. D. Structure and function of type II DNA topoisomerases. Biochem. J. 1994, 303, 681-695.
9. Nitiss, J. L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta 1998, 1400, 63-81.
10. Kellner, U.; Sehested, M.; Jensen, P. B.; Gieseler, F.; Rudolph, P. Culprit and victim - DNA topoisomerase II. Lancet Oncol. 2002, 4, 235-243.
11. Pommier, Y. In Cancer Therapeutics: Experimental and Clinical Agents; Teicher, B. A., Ed.; Humana Press: Totowa, NJ, 1997; pp 153-174.
12. Pommier, Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother. Pharmacol. 1993, 32, 103-108.
13. Corbett, A. H.; Osheroff, N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol. 1993, 6, 585-597.
14. Osheroff, N.; Corbett, A. H.; Robinson, M. J. Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv. Pharmacol. 1994, 29B, 105-126.
15. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 1989, 58, 351-375.
16. Chen, A. Y.; Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 1994, 34, 191-218.
17. Vladu, B.; Woynarowski, J. M.; Manikumar, G.; Wani, M. C.; Wall, M. E.; Von Hoff, D. D.; Wadkins, R. M. 7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents. Mol. Pharmacol. 2000, 57, 243-251.
18. Chu, D. T. W.; Hallas, R.; Clement, J. J.; Alder, L.; McDonald, E.; Plattner, J. J. Synthesis and antitumour activities of quinolone antineoplastic agents. Drugs Exp. Clin. Res. 1992, 18, 275-282.
19. Permana, P. A.; Snapka, R. M.; Shen, L. L.; Chu, D. T.; Clement, J. J.; Plattner, J. J. Quinobenzoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry 1994, 33, 11333-11339.
20. Clement, J. J.; Burres, N.; Jarvis, K.; Chu, D. T. W.; Swiniarski, J.; Adler, J. Biological characterization of a novel antitumor quinolone. Cancer Res. 1995, 55, 830-835.
21. 2+ complex on DNA: a new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex. J. Med. Chem. 1995, 38, 408-424.
22. 2+-dependent photochemical DNA cleavage by the antitumor quinobenzoxazine (S)-A-62176. Biochemistry 2000, 39, 10236-10246.
23. 2+ self-assembly model formed in the presence of topoisomerase II. J. Biol. Chem. 1999, 274, 17226-17235.
24. Cirilli, M.; Bachechi, F.; Ughetto, G.; Colonna, F. P.; Capobianco, M. L. Interactions between morpholinyl anthracyclines and DNA. The crystal structure of a morpholino doxorubicin bound to d(CGTACG). J. Mol. Biol. 1992, 230, 878-889.
25. Bigi, F.; Casiraghi, G.; Casnati, G.; Sartori, G. Modification of the Nickl reaction. A general synthetic approach to 20-vinyl-2,3-dihydrobenzofurans. Tetrahedron 1983, 39, 169-174.
26. Habib, A. M.; Ho, D. K.; Masuda, S.; McCloud, T.; Reddy, K. S.; Aboushoer, M.; McKenzie, A.; Byrn, S. R.; Chang, C.-J.; Cassady, M. Structure and stereochemistry of psorospermin and related cytotoxic dihydrofuranoxanthones from Psorospermum febrifugum. J. Org. Chem. 1987, 52, 412-418.
27. Zeng, Q.; Kwok, Y.; Kerwin, S. M.; Mangold, G.; Hurley, L. H. Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. J. Med. Chem. 1998, 41, 4273-4278.
28. th ed.; Isselbacher, K. J., et al., Eds.; McGraw-Hill: New York, 1998; pp 523-537.
29. Hurley, L. H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2002, 2, 188-200.
30. Kim, M.-Y.; Duan, W.; Guzman, M.; Hurley, L. H. Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes. J. Med. Chem. 2003, 46, 571-583.
31. Discover, version 2.9.5 (molecular mechanics force fields), Insight II (molecular modeling software); Accelrys Inc., 9685 Scranton Road, San Diego, CA, 92121; 2000.
32. Maple, J. P.; Hwang, M.-J.; Jalkanen, K. J.; Stockfisch, T. P.; Hagler, A. T. Derivation of class II force fields: V. Quantum force field for amides, peptides, and related compounds. J. Comput. Chem. 1998, 19, 430-458.
33. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
34. Luty, B. A.; Wasserman, Z. R.; Stouten, P. F. W.; Hodge, C. N.; Zacharias, M.; McCammon, J. A. A molecular mechanics/grid method for evaluation of ligand-receptor interactions. J. Comput. Chem. 1995, 16, 454-464.
35. Stouten, P. F. W.; Frömmel, C.; Nakamura, H.; Sander, C. An effective solvation term based on atomic occupancies for use in protein simulations. Mol. Simul. 1993, 10, 97-120.
36. Insight II (molecular modeling software); Accelrys Inc., 9685 Scranton Road, San Diego, CA, 92121; 2000.
37. Garemyr, R.; Elofsson, A. Study of the electrostatics treatment in molecular dynamics simulations. Proteins: Struct., Funct., Genet. 1999, 37, 417-428.
38. Orozco, M.; Laughton, C. A.; Herzyk, P.; Neidle, S. Molecular-mechanics modelling of drug-DNA structures: the effects of differing dielectric treatment on helix parameters and comparison with a fully solvated structural model. J. Biomol. Struct. Dyn. 1990, 8, 359-373.
39. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
40. Jorgensen, W. L.; Chandresekhar, J.; Madura, J. D. Comparison of simple potential functions for simulated liquid water. J. Chem. Phys. 1983, 79, 926-935.
41. Andersen, H. C. RATTLE: a "velocity" version of the SHAKE algorithm for molecular dynamics calculations. J. Comput. Phys. 1983, 52, 24-34.
42. Åqvist, J.; Medina, C.; Samuelsson, J. E. A new method for predicting binding affinity in computer-aided drug design. Protein Eng. 1994, 7, 385-391.
43. Åqvist, J. Calculation of absolute binding free energies for charged ligands and effects of long-range electrostatic interactions. J. Comput. Chem. 1996, 17, 1587-1597.